Latest Insider Transactions at Selecta Biosciences Inc (SELB)
This section provides a real-time view of insider transactions for Selecta Biosciences Inc (SELB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SELECTA BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SELECTA BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
32,789
-39.12%
|
$524,624
$16.67 P/Share
|
|
Nov 21
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,789
+28.12%
|
$32,789
$1.41 P/Share
|
|
Nov 20
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+25.95%
|
$42,000
$3.23 P/Share
|
|
Nov 20
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
5,700
-5.03%
|
$96,900
$17.69 P/Share
|
|
Nov 20
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+9.13%
|
$5,700
$1.41 P/Share
|
|
Nov 19
2024
|
Michael Singer Director |
SELL
Bona fide gift
|
Direct |
28,821
-24.07%
|
-
|
|
Nov 19
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
200
-0.39%
|
$3,800
$19.5 P/Share
|
|
Nov 19
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.39%
|
$200
$1.41 P/Share
|
|
Nov 18
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
58,295
+0.34%
|
$1,049,310
$18.19 P/Share
|
|
Nov 18
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
34,400
-22.65%
|
$619,200
$18.39 P/Share
|
|
Nov 18
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,400
+28.71%
|
$34,400
$1.41 P/Share
|
|
Nov 15
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
277,246
+3.2%
|
$4,713,182
$17.09 P/Share
|
|
Nov 15
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
22,068
-30.19%
|
$375,156
$17.2 P/Share
|
|
Nov 15
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,068
+23.19%
|
$22,068
$1.41 P/Share
|
|
Nov 15
2024
|
Milos Miljkovic Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-52.26%
|
$340,000
$17.14 P/Share
|
|
Nov 15
2024
|
Milos Miljkovic Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+34.32%
|
$60,000
$3.23 P/Share
|
|
Nov 15
2024
|
Christopher M Jewell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,065
-38.25%
|
$273,105
$17.06 P/Share
|
|
Nov 15
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,065
+27.66%
|
$48,195
$3.23 P/Share
|
|
Nov 14
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
96,399
+0.59%
|
$1,542,384
$16.58 P/Share
|
|
Nov 14
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
25,900
-17.87%
|
$414,400
$16.7 P/Share
|
|
Nov 14
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,900
+25.19%
|
$25,900
$1.41 P/Share
|
|
Nov 14
2024
|
Milos Miljkovic Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
35,000
-65.7%
|
$560,000
$16.13 P/Share
|
|
Nov 14
2024
|
Milos Miljkovic Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+39.65%
|
$105,000
$3.23 P/Share
|
|
Nov 14
2024
|
Christopher M Jewell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
36,050
-35.1%
|
$576,800
$16.68 P/Share
|
|
Nov 14
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,050
+36.77%
|
$108,150
$3.23 P/Share
|
|
Oct 11
2024
|
Murat Kalayoglu Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,518,373
+25.0%
|
-
|
|
Oct 11
2024
|
Elizabeth Hoge > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,518,373
+25.0%
|
-
|
|
Oct 04
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
80,301
+0.25%
|
$1,766,622
$22.8 P/Share
|
|
Oct 03
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
119,906
+0.3%
|
$2,398,120
$20.09 P/Share
|
|
Oct 02
2024
|
Timothy A Springer Director |
BUY
Other acquisition or disposition
|
Indirect |
317,879
+49.01%
|
-
|
|
Oct 02
2024
|
Timothy A Springer Director |
SELL
Other acquisition or disposition
|
Indirect |
2,119,193
-80.0%
|
-
|
|
Oct 02
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
5,514
+0.07%
|
$93,738
$17.38 P/Share
|
|
Oct 02
2024
|
Timothy A Springer Director |
BUY
Other acquisition or disposition
|
Direct |
1,801,314
+18.73%
|
-
|
|
Sep 25
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
722,668
+15.33%
|
-
|
|
Sep 25
2024
|
Timothy A Springer Director |
SELL
Exercise of conversion of derivative security
|
Indirect |
722,668
-100.0%
|
-
|
|
Sep 25
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,636,832
+21.39%
|
-
|
|
Sep 25
2024
|
Timothy A Springer Director |
SELL
Exercise of conversion of derivative security
|
Direct |
1,636,832
-100.0%
|
-
|
|
Aug 12
2024
|
Timothy C Barabe Director |
BUY
Open market or private purchase
|
Direct |
7,500
+25.63%
|
$90,000
$12.7 P/Share
|
|
Aug 12
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
8,016
+41.06%
|
$96,192
$12.72 P/Share
|
|
Jul 02
2024
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Indirect |
722,668
+50.0%
|
$14,453,360
$20.0 P/Share
|
|
Jul 02
2024
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,636,832
+50.0%
|
$32,736,640
$20.0 P/Share
|
|
Jul 01
2024
|
Kemal Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,933
+50.0%
|
-
|
|
Apr 08
2024
|
Michael Singer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
643,630
+49.57%
|
-
|
|
Apr 08
2024
|
Michael Singer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
110,151
+47.91%
|
-
|
|
Apr 08
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
826,169
+30.0%
|
-
|
|
Apr 08
2024
|
Timothy A Springer Director |
SELL
Exercise of conversion of derivative security
|
Indirect |
24,785
-100.0%
|
-
|
|
Apr 08
2024
|
Timothy A Springer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,130,846
+48.54%
|
-
|
|
Apr 08
2024
|
Timothy A Springer Director |
SELL
Exercise of conversion of derivative security
|
Direct |
123,925
-100.0%
|
-
|
|
Apr 08
2024
|
Murat Kalayoglu Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,926,764
+49.08%
|
-
|
|
Apr 08
2024
|
Murat Kalayoglu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
491,853
+49.27%
|
-
|